As South Africa grapples with a persistent tuberculosis (TB) epidemic, the Department of Health has expressed optimism about the ongoing development of a new vaccine that could alter the landscape of TB prevention and control, Cape {town} Etc reports. Recent trials of the M72/AS01E vaccine have shown promising results, advancing to Phase 3 trials in South Africa, Kenya, Zambia, Malawi, and Indonesia. Should the new vaccine succeed in its trials, it would be the first TB vaccine introduced in over a century, a monumental development in global public health. This agreement stipulates the production and release of the vaccine on a global scale, which also opens avenues for local manufacturing in South Africa and Indonesia. Such collaboration not only has the potential to revolutionise TB prevention but also promises to stimulate economic growth within the nation.